NCT04285268 2026-01-30
Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Rutgers, The State University of New Jersey
Phase 2 Withdrawn
Clinical Trials
243 trialsNCT03135743 2026-01-16
LYMPHOSYNCHRO
Centre Hospitalier Universitaire, Amiens
Withdrawn
NCT07071909 2026-01-06
Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Withdrawn
NCT04091009 2025-12-31
Effect of Standard of Care Reduced Dose Versus Full Dose Buprenorphine/Naloxone in the Perioperative Period on Pain Control and Post-Operative Opioid Use Disorder Symptoms
Massachusetts General Hospital
Phase 4 Withdrawn
NCT06013904 2025-07-04
Difficult PIV Placement in the Pediatric ED
University of Texas at Austin
Phase NA Withdrawn
NCT05538988 2025-06-27
BIOSELECT
AHS Cancer Control Alberta
Phase 1/2 Withdrawn
NCT05106192 2025-06-12
Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System.
Case Comprehensive Cancer Center
Phase NA Withdrawn
NCT04685915 2025-05-22
Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT04694560 2025-05-16
A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Memorial Sloan Kettering Cancer Center
Withdrawn
NCT04556266 2025-05-13
A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies
Memorial Sloan Kettering Cancer Center
Phase 1 Withdrawn
NCT06290622 2025-05-06
PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL
University of Alabama at Birmingham
Phase 1 Withdrawn
NCT02548468 2025-05-02
Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant in Treating Patients With Advanced Cutaneous T Cell Lymphoma
Thomas Jefferson University
Phase 1 Withdrawn
NCT03288818 2025-04-29
Low Dose Total Skin Electron Beam Radiation Therapy and Mechlorethamine Hydrochloride Gel in Treating Patients With Mycosis Fungoides
Thomas Jefferson University
Phase 2 Withdrawn
NCT04781855 2025-02-28
Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT03939585 2024-12-05
Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT
Case Comprehensive Cancer Center
Phase 1 Withdrawn
NCT05487495 2024-11-14
Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma
Beijing Boren Hospital
Phase 1 Withdrawn
NCT06003179 2024-11-12
LOKI
University Health Network, Toronto
Phase 1 Withdrawn
NCT04523623 2024-10-26
Pain Control Differences Between Oxycodone and Ibuprofen in Children With Isolated Forearm Injuries
Washington University School of Medicine
Phase NA Withdrawn
NCT05134740 2024-10-22
pediTACTAL
Baylor College of Medicine
Phase 1 Withdrawn
NCT05521178 2024-10-15
Cardiotoxicities in Patients Receiving BTKi
Dana-Farber Cancer Institute
Withdrawn
NCT04575064 2024-10-09
An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANY
Klinikum Bremen-Mitte, gGmbH
Phase 2/3 Withdrawn
NCT02298816 2024-10-03
HMvax-Regist
Wake Forest University Health Sciences
Withdrawn
NCT04322084 2024-09-25
Continuous Ambulatory Monitoring to Predict Elevated Risk of Infection in Children With Lymphoblastic Leukemia Undergoing Induction Chemotherapy (CAMPER-ALL)
St. Jude Children's Research Hospital
Withdrawn
NCT05784844 2024-09-19
Antimicrobial Revision in Persistent Febrile Neutropenia
Wake Forest University Health Sciences
Phase 4 Withdrawn
NCT04996745 2024-08-26
Taking POSNA's OrthoKids to the People
Louisiana State University Health Sciences Center in New Orleans
Phase NA Withdrawn
NCT01843868 2024-08-07
Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP
Australasian Leukaemia and Lymphoma Group
Phase NA Withdrawn
NCT05936229 2024-07-12
Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy
Fred Hutchinson Cancer Center
Phase 1/2 Withdrawn
NCT05740449 2024-06-21
HEM-iSMART A
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Withdrawn
NCT05966233 2024-05-21
FIL_POLARDHAP
Fondazione Italiana Linfomi - ETS
Phase 2 Withdrawn
NCT05895201 2024-04-29
High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD
Indiana University
Phase 1/2 Withdrawn
NCT04995536 2024-04-25
CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL
City of Hope Medical Center
Phase 1 Withdrawn
NCT05465876 2024-04-04
PACE-CLL
Sunnybrook Health Sciences Centre
Phase 2 Withdrawn
NCT03098355 2024-03-18
Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies
Zhujiang Hospital
Phase 1/2 Withdrawn
NCT05613348 2024-03-18
CAR19T2
Zhujiang Hospital
Phase 1/2 Withdrawn
NCT03982992 2024-03-12
DLI-TARGET
Ludwig-Maximilians - University of Munich
Phase 2 Withdrawn
NCT05796271 2024-02-29
Clinical Trial of Roflumilast Added to Standard Chemoimmunotherapy
The University of Texas Health Science Center at San Antonio
Phase 1 Withdrawn
NCT04845035 2024-02-22
Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
University of Michigan Rogel Cancer Center
Phase 2 Withdrawn
NCT04220008 2024-01-12
Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT05201183 2023-12-11
A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies
Indiana University
Phase 1/2 Withdrawn
NCT05321940 2023-12-04
Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias
University of Miami
Phase 1 Withdrawn
NCT05929716 2023-11-13
An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT04684979 2023-11-01
Transplantation of Hematopoietic Stem Cells From HLA-compatible Donors in Patients With B-Cell Lymphoid Malignancies
Baptist Health South Florida
Phase 2 Withdrawn
NCT04795869 2023-10-10
Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma
Northwestern University
Phase 2 Withdrawn
NCT05961696 2023-10-10
A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT03884972 2023-09-25
Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT04952584 2023-09-07
Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas
Baylor College of Medicine
Phase 1 Withdrawn
NCT05519527 2023-08-31
STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL Amyloidosis
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT04231734 2023-08-28
Ketogenic Diet in Patients With Untreated Low Tumor Burden Mantle Cell Lymphoma
Weill Medical College of Cornell University
Phase NA Withdrawn
NCT04029038 2023-08-21
Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT00816413 2023-08-14
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer
University of Nebraska
Phase 1/2 Withdrawn